# Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

> **NCT05695781** · PHASE3 · COMPLETED · sponsor: **BRIM Biotechnology Inc.** · enrollment: 740 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** BRM421 Ophthalmic Solution
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05695781
- **Lead sponsor:** BRIM Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-27
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 740 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05695781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05695781, "Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05695781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*